Genocea Biosciences's total liabilities is $26M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Genocea Biosciences (GNCA) currently reports a total liabilities of $26M as of March 2022. That compares with $82M in the prior-year period — down 67.9% year over year. Use the charts on this page to explore Genocea Biosciences's total liabilities history and peer comparisons.
Genocea Biosciences's total liabilities decreased from $82M to $26M — a 67.9% year-over-year decrease (period ending March 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Genocea Biosciences reported $26M in total liabilities as of March 2022. That compares with $82M in the prior-year period — down 67.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total liabilities of $26M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Genocea Biosciences, and consider following GNCA for alerts when major investors trade the stock.
Genocea Biosciences is classified in the Healthcare sector. On total liabilities, it currently shows $26M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GNCA with unrelated industries.